Browse by Clinical Topic:


Featured CME/CE Content:
 
neuroscienceCME Editors' Picks:



Real-world Tactics to Address Health Inequities in Lung Cancer Care

Premiere Date: Monday, September 19, 2022

This activity offers CE credit for:

  1. Certified Case Managers (CCMC)
  2. ABIM (MOC)
  3. Medicine (accme)
  4. Nursing (ANCC)
  5. Pharmacy (acpe)
  6. PA (aapa)
  7. Dietetic Registration (CDR)
  8. Other


All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Friday, September 19, 2025

Faculty


Edith Peterson Mitchell, MD, MACP, FCPP, FRCPEdith Peterson Mitchell, MD, MACP, FCPP, FRCP (Moderator)
Clinical Professor of Medicine and Medical Oncology
Department of Medical Oncology
Director, Center to Eliminate Cancer Disparities
Associate Director, Diversity Affairs
Sidney Kimmel Cancer Center at Jefferson
Philadelphia, PA
116th President of the National Medical Association

Ana I. Velázquez Mañana, MD, MScAna I. Velázquez Mañana, MD, MSc 
(she/her/ella)
Assistant Professor, Division of Hematology/Oncology
Assistant Director of Diversity, Equity, Inclusion and Accessibility
UCSF Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, CA

Statement of Need

Despite lung cancer being the leading cause of cancer mortality, its survival rate has continued to increase over the past 5 years. However, disparities in early diagnosis, treatment options and access, survival rate, and more remain for racial and ethnic underserved populations. A culmination of biases, disparities, and inequities continues a cycle of inadequate oncological treatment for lung cancer, thus resulting in delayed diagnosis and suboptimal clinical management, prognosis, and survival rate.

In this CME Outfitters BriefCase, a faculty expert will guide learners through a patient case scenario reflecting the impact of biases, disparities, and health inequities that reduce the quality of oncology care for racial and ethnic underserved patients with lung cancer. This program will provide actionable strategies, empowering attendees to recognize factors and implement changes in practice to improve lung cancer treatment.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Recognize the impact of health inequities on patients with lung cancer and develop individual treatment strategies for optimal clinical outcomes

Financial Support

Supported by an educational grant from the Johnson & Johnson Institute and the Johnson & Johnson Family of Companies.

Target Audience

Physicians, PAs, NPs, nurses/nurse navigators, dietitians, pharmacists, specializing in oncology, pathology, radiology, pulmonology, and primary care.

Credit Information

CCMC Credit (Certified Case Managers):
This program has been approved for 0.5 CE credits by the Commission for Case Manager Certification (CCMC).

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning formats: Enduring material

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 0.5 contact hours

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Mitchell reports the following financial relationships:

Advisory Board: Corvus Pharmaceuticals, Inc.

Consultant: Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; Genentech, Inc.; and SEMA4 OpCo, Inc.

Dr. Velázquez Mañana reports the following financial relationships:

Stock Shareholder (directly purchased): Corbus Pharmaceuticals Holdings, Inc.

Other Financial or Material Support: LEAD Conference advisory committee member organized by BioAscend; Stipend from MDOutlook and Curio Science; and Travel Support from DAVA Oncology

The following peer reviewer and CME Outfitters staff have no financial relationships:
  • Michael Franks, APRN, AGACNP-BC, FNP-BC (peer reviewer)
  • Meghann Taft-Lockard (planning committee)
  • David Modrak, PhD (planning committee)
  • Sandra Caballero, PharmD (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sharon Tordoff (planning committee)


  • Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

    Questions about this activity? Call us at 877.CME.PROS (877.263.7767).

    BC-070-091922-57

    Home      |      Register/Log In      |      Activities      |      Communities of Practice      |      About      |      Download